Nafarelin acetate(76932-56-4 free base)
Chemical Structure Depiction of
Nafarelin acetate(76932-56-4 free base)
Nafarelin acetate(76932-56-4 free base)
Compound characteristics
| Compound ID: | CE02-5334 |
| Compound Name: | Nafarelin acetate(76932-56-4 free base) |
| Molecular Weight: | 1400.57 |
| Molecular Formula: | C66 H83 N17 O13.C2 H4 O2.H2 O |
| CAS Number: | 76932-60-0 |
| Smiles: | CC(C)C[C@@H](C(N[C@@H](CCCN=C(N)N)C(N1CCC[C@H]1C(NCC(N)=O)=O)=O)=O)NC([C@@H](Cc1ccc2ccccc2c1)NC([C@H](Cc1ccc(cc1)O)NC([C@H](CO)NC([C@H](Cc1c[nH]c2ccccc12)NC([C@H](Cc1cnc[nH]1)NC([C@@H]1CCC(N1)=O)=O)=O)=O)=O)=O)=O.CC(O)=O.O |
| InChI Key: | FSBTYDWUUWLHBD-WBYGOTRNSA-N |
| Short Description: | Nafarelin acetate(76932-56-4 free base) (RS-94991-298) is a GnRH agonist that acts as an analog of GnRH. Nafarelin acetate(76932-56-4 free base) causes a decrease in the pituitary secretion of gonadot ropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It may be used in the treatment of estrogen-dependent conditions. |
| Pathway: | GPCR/G Protein |
| Target: | GNRH Receptor |
| Type of molecule: | FDA Approved/clinical |
| Alias: | RS-94991-298 , Nafarelin acetate , Nafarelin acetate hydrate , Synarel |
| Stock amount: | 850 |